Comparative Pharmacology
Head-to-head clinical analysis: ELELYSO versus MYOZYME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELELYSO versus MYOZYME.
ELELYSO vs MYOZYME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human glucocerebrosidase; hydrolyzes glucocerebroside to glucose and ceramide, reducing accumulated glucocerebroside in lysosomes of macrophages.
Alglucosidase alfa is a recombinant form of human acid alpha-glucosidase (GAA) that hydrolyzes glycogen to glucose in lysosomes. It replaces deficient GAA enzyme activity in patients with Pompe disease.
60 U/kg administered intravenously over 60 minutes every 2 weeks.
20 mg/kg IV every 2 weeks.
None Documented
None Documented
Mean terminal elimination half-life ranges from 6.1 to 8.9 minutes after intravenous infusion; rapid clearance due to receptor-mediated uptake.
The terminal elimination half-life of alglucosidase alfa is approximately 2.3 hours at steady state. This short half-life necessitates weekly intravenous infusions to maintain therapeutic enzyme levels in target tissues.
Primarily catabolized via peptide hydrolysis; renal excretion of small peptide fragments and amino acids; less than 1% excreted unchanged in urine.
Renal elimination is the primary route of clearance for alglucosidase alfa. Following intravenous administration, the drug is cleared via catabolism into small peptides and amino acids, which are then excreted renally. Less than 5% of the administered dose is excreted unchanged in urine. Biliary/fecal elimination is negligible.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy